Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period
| Autor: | Patrice Belanger, Mark T. Butt, Thomas Cummings, Mark G. Evans, Mark Zorbas, Jessica-lyn Gremminger |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Pathology medicine.medical_specialty Tanezumab Stellate Ganglion Satellite Cells Perineuronal Antibodies Monoclonal Humanized Placebo 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound 0302 clinical medicine medicine Animals Gliosis Analgesics Endocrine and Autonomic Systems Satellite glial cell business.industry Chronic pain medicine.disease Ganglion Macaca fascicularis medicine.anatomical_structure chemistry Toxicity Monoclonal Female Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Autonomic Neuroscience. 218:51-53 |
| ISSN: | 1566-0702 |
| Popis: | Tanezumab, a humanized monoclonal anti-NGF antibody, has demonstrated efficacy and safety profiles in Phase III clinical trials of chronic pain. In a 24-week study in non-human primates, morphological observations of sympathetic ganglia showed decreased ganglia volume, decreased neuronal size, and increased glial cell density compared with controls after 3 tanezumab treatments. Using stereological techniques to quantify glial cells, the present 26-week study found no significant difference after weekly treatments in total cervicothoracic ganglia satellite glial cell number between placebo- or tanezumab-treated cynomolgus monkeys. These findings suggest that tanezumab treatment does not result in a true gliosis in sympathetic ganglia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect